PROTEOSTASIS THERAPEUTICS, INC. | Business Operations | Business Contracts

Termination Agreement by and between Yumanity Therapeutics, Inc. and MIL 40, LLC dated as of February 28, 2022 (Filed With SEC on March 4, 2022)

Contingent Value Rights Agreement, dated as of December 22, 2020 by and among the Company and Shareholder Representative Services LLC (Filed With SEC on December 30, 2020)

Form of Director and Officer Indemnification Agreements (Filed With SEC on December 30, 2020)

Sales Agreement dated May 9, 2019 by and between Proteostasis Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on May 9, 2019)

Amendment No. 6 to Collaboration and License Agreement dated April 23, 2018 by and between the Company and Astellas Pharma Inc (Filed With SEC on August 8, 2018)

Sales Agreement dated March 23, 2018 by and between Proteostasis Therapeutics, Inc. and Leerink Partners LLC (Filed With SEC on March 23, 2018)

Amendment No. 5 to Collaboration and License Agreement (Filed With SEC on August 15, 2016)

Amendment No. 4 to Collaboration and License Agreement (Filed With SEC on May 27, 2016)

RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Proteostasis Therapeutics, Inc. and Cystic FibrosisFoundation Therapeutics, Inc. Dated March 20, 2012 (Filed With SEC on December 23, 2015)

COLLABORATION AND LICENSEAGREEMENT BETWEEN ASTELLAS PHARMA INC. AND PROTEOSTASIS THERAPEUTICS, INC. (Filed With SEC on December 23, 2015)

PROTEOSTASIS THERAPEUTICS, INC. FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on December 23, 2015)

Amendment No. 2 to Collaboration and License Agreement (Filed With SEC on December 23, 2015)

Amendment No. 3 to Collaboration and License Agreement (Filed With SEC on December 23, 2015)

PROTEOSTASIS THERAPEUTICS, INC. (126) | Business Operations (13)